company background image
CLIN

Clinigen GroupAIM:CLIN Stock Report

Market Cap

UK£1.2b

7D

44.3%

1Y

42.3%

Updated

08 Dec, 2021

Data

Company Financials +
CLIN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance5/6
Financial Health2/6
Dividends2/6

CLIN Stock Overview

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally.

Clinigen Group Competitors

Sartorius

XTRA:SRT

€36.2b

Genmab

CPSE:GMAB

kr.172.0b

Charles River Laboratories International

NYSE:CRL

US$18.5b

argenx

ENXTBR:ARGX

€13.5b

Price History & Performance

Summary of all time highs, changes and price drops for Clinigen Group
Historical stock prices
Current Share PriceUK£9.10
52 Week HighUK£9.12
52 Week LowUK£5.42
Beta1.27
1 Month Change52.56%
3 Month Change37.98%
1 Year Change42.30%
3 Year Change8.59%
5 Year Change26.92%
Change since IPO417.04%

Recent News & Updates

Nov 17
Increases to CEO Compensation Might Be Put On Hold For Now at Clinigen Group plc (LON:CLIN)

Increases to CEO Compensation Might Be Put On Hold For Now at Clinigen Group plc (LON:CLIN)

Shareholders of Clinigen Group plc ( LON:CLIN ) will have been dismayed by the negative share price return over the...

Shareholder Returns

CLINGB Life SciencesGB Market
7D44.3%-0.3%1.4%
1Y42.3%25.2%12.1%

Return vs Industry: CLIN exceeded the UK Life Sciences industry which returned 21.1% over the past year.

Return vs Market: CLIN exceeded the UK Market which returned 12.4% over the past year.

Price Volatility

Is CLIN's price volatile compared to industry and market?
CLIN volatility
CLIN Average Weekly Movement9.0%
Life Sciences Industry Average Movement7.9%
Market Average Movement5.0%
10% most volatile stocks in GB Market10.0%
10% least volatile stocks in GB Market2.6%

Stable Share Price: CLIN is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CLIN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20081,069Shaun Chiltonhttps://www.clinigengroup.com

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch.

Clinigen Group Fundamentals Summary

How do Clinigen Group's earnings and revenue compare to its market cap?
CLIN fundamental statistics
Market CapUK£1.20b
Earnings (TTM)UK£39.70m
Revenue (TTM)UK£523.60m

30.6x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLIN income statement (TTM)
RevenueUK£523.60m
Cost of RevenueUK£325.60m
Gross ProfitUK£198.00m
ExpensesUK£158.30m
EarningsUK£39.70m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.30
Gross Margin37.82%
Net Profit Margin7.58%
Debt/Equity Ratio88.8%

How did CLIN perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

25%

Payout Ratio

Valuation

Is Clinigen Group undervalued compared to its fair value and its price relative to the market?

18.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLIN (£9.1) is trading below our estimate of fair value (£11.21)

Significantly Below Fair Value: CLIN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CLIN is good value based on its PE Ratio (30.6x) compared to the European Life Sciences industry average (44.7x).

PE vs Market: CLIN is poor value based on its PE Ratio (30.6x) compared to the UK market (19.4x).


Price to Earnings Growth Ratio

PEG Ratio: CLIN is poor value based on its PEG Ratio (5.9x)


Price to Book Ratio

PB vs Industry: CLIN is good value based on its PB Ratio (2.7x) compared to the GB Life Sciences industry average (4.5x).


Future Growth

How is Clinigen Group forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

5.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLIN's forecast earnings growth (5.2% per year) is above the savings rate (0.9%).

Earnings vs Market: CLIN's earnings (5.2% per year) are forecast to grow slower than the UK market (12.6% per year).

High Growth Earnings: CLIN's earnings are forecast to grow, but not significantly.

Revenue vs Market: CLIN's revenue (6.5% per year) is forecast to grow faster than the UK market (4.8% per year).

High Growth Revenue: CLIN's revenue (6.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLIN's Return on Equity is forecast to be high in 3 years time (20.3%)


Past Performance

How has Clinigen Group performed over the past 5 years?

12.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLIN has high quality earnings.

Growing Profit Margin: CLIN's current net profit margins (7.6%) are higher than last year (3%).


Past Earnings Growth Analysis

Earnings Trend: CLIN's earnings have grown by 12.7% per year over the past 5 years.

Accelerating Growth: CLIN's earnings growth over the past year (179.6%) exceeds its 5-year average (12.7% per year).

Earnings vs Industry: CLIN earnings growth over the past year (179.6%) exceeded the Life Sciences industry 77.1%.


Return on Equity

High ROE: CLIN's Return on Equity (8.9%) is considered low.


Financial Health

How is Clinigen Group's financial position?


Financial Position Analysis

Short Term Liabilities: CLIN's short term assets (£302.7M) exceed its short term liabilities (£172.8M).

Long Term Liabilities: CLIN's short term assets (£302.7M) do not cover its long term liabilities (£445.8M).


Debt to Equity History and Analysis

Debt Level: CLIN's net debt to equity ratio (70.2%) is considered high.

Reducing Debt: CLIN's debt to equity ratio has increased from 40.5% to 88.8% over the past 5 years.

Debt Coverage: CLIN's debt is not well covered by operating cash flow (11.4%).

Interest Coverage: CLIN's interest payments on its debt are well covered by EBIT (5.3x coverage).


Balance Sheet


Dividend

What is Clinigen Group current dividend yield, its reliability and sustainability?

0.84%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CLIN's dividend (0.84%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.36%).

High Dividend: CLIN's dividend (0.84%) is low compared to the top 25% of dividend payers in the UK market (4.11%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, CLIN has been paying a dividend for less than 10 years.

Growing Dividend: CLIN's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (25.5%), CLIN's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CLIN's dividends in 3 years are forecast to be thoroughly covered by earnings (15% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Shaun Chilton (53 yo)

5.08yrs

Tenure

UK£955,000

Compensation

Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016 & has the responsibility for the Group achieving its KPIs and plays a central role in setting the...


CEO Compensation Analysis

Compensation vs Market: Shaun's total compensation ($USD1.26M) is about average for companies of similar size in the UK market ($USD1.52M).

Compensation vs Earnings: Shaun's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CLIN's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: CLIN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Clinigen Group plc's employee growth, exchange listings and data sources


Key Information

  • Name: Clinigen Group plc
  • Ticker: CLIN
  • Exchange: AIM
  • Founded: 2008
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£1.200b
  • Shares outstanding: 133.36m
  • Website: https://www.clinigengroup.com

Number of Employees


Location

  • Clinigen Group plc
  • Pitcairn House
  • Crown Square
  • Burton Upon Trent
  • Staffordshire
  • DE14 2WW
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/08 22:06
End of Day Share Price2021/12/08 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.